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Abstract
Streptococcus pneumoniae infections are often difﬁcult to diagnose accurately, as it is not uncommon for clinical samples to be culture-
negative, particularly after antibiotic administration. The rapid Binax NOW S. pneumoniae urinary antigen test lacks speciﬁcity in chil-
dren, owing to pneumococcal antigen reactions in children who are nasopharyngeal carriers of S. pneumoniae. A western blot assay with
a speciﬁc polyclonal antibody was developed for direct detection of the putative proteinase maturation protein A (PpmA) in urine sam-
ples from children with pneumococcal infections. The sensitivity and speciﬁcity of the assay were 66.7% and 100%, respectively. Previous
antibiotic treatment or S. pneumoniae nasopharyngeal colonization did not affect PpmA antigenuria. Results also demonstrated the pres-
ence of PpmA cross-reactive epitopes in commensal bacteria that co-colonize the nasopharyngeal niche, although the non-pneumococcal
cross-reactive protein(s) did not interfere with the detection assay. S. pneumoniae PpmA in the urine of children with pneumococcal
infections may be a marker that has the potential to be used in the clinical diagnosis of pneumococcal infection.
Keywords: Diagnosis, pneumococcal infection, proteinase maturation protein A (PpmA), Streptococcus pneumoniae, urine
Original Submission: 7 June 2008; Revised Submission: 6 August 2008; Accepted: 7 August 2008
Editor: F. Allerberger
Clin Microbiol Infect 2009; 15: 443–453
Corresponding author and reprint requests: M. Del Mar
Garcı´a-Sua´rez, A´rea de Microbiologı´a, Facultad de Medicina,
C/Julia´n Claverı´a, 6, 33006 Oviedo, Asturias, Spain
E-mail: garciamar@uniovi.es
Introduction
Streptococcus pneumoniae is an important human pathogen
that causes meningitis, otitis media, sepsis, and pneumonia.
Accurate and rapid diagnosis of pneumococcal infections is
critical, because they entail substantial morbidity and mortal-
ity worldwide [1,2]. The current reference standard for the
diagnosis of S. pneumoniae infections is the isolation of the
organism in culture from normally sterile body ﬂuids. How-
ever, the sensitivity of diagnostic cultures has been shown
to be low, and it takes at least 2 days to obtain a result [3].
C-polysaccharide is a cell wall component of S. pneumoniae
that can be detected in the urine of patients suffering from
pneumococcal infections. A rapid urinary pneumococcal anti-
gen test (Binax NOW S. pneumoniae urinary antigen test;
Binax Inc., Portland, ME, USA) is available for the detection
of this antigen in patients; however, C-polysaccharide is also
present in small amounts in the urine of healthy children
[4,5]. S. pneumoniae present in the nasopharynx is the most
likely antigen source in pneumococcal carriers testing positive
when this assay is used [6]. Positive results in non-carriers
might be due to undetected, low-level pneumococcal coloni-
zation, or colonization by Streptococcus mitis, which has
been shown to harbour pneumococcal C-polysaccharide-like
antigens [7]. Furthermore, urine samples can remain positive
for weeks after a pneumococcal infection, and the test will
also be affected if the patient has been vaccinated with a
pneumococcal conjugate vaccine shortly before the test [6].
Hence, it is doubtful whether this assay is useful for
discriminating between children with and without pneumo-
coccal infections, particularly in developing countries, where
nasopharyngeal colonization rates are high [8]. Molecular
biology-based techniques, including PCR assays and DNA
hybridization assays, have been reported for the rapid, spe-
ciﬁc, and sensitive detection of microorganisms in blood
samples [9,10]. More recently, a sensitive and speciﬁc ELISA
has been developed to detect pneumolysin in urine samples,
thereby allowing differentiation between healthy carriers and
patients [11].
The putative proteinase maturation protein A (PpmA)
of S. pneumoniae is homologous to members of the family
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of peptidyl-prolyl cis–trans isomerases (PPIases), which
accelerate the rate-limiting cis–trans or trans–cis conforma-
tional changes at X-Pro bonds during protein folding [12].
There are three distinct families within the enzyme class
of PPIases: the cyclophilins, the FK506-binding proteins,
and the parvulins. PpmA is homologous to the members
of the parvulin family. Although PPIase activity has never
been demonstrated, the protein is considered to be
involved in enzyme secretion and activation, and it is a
surface-located immunogenic lipoprotein that contributes
to bacterial virulence [13,14]. PpmA is conserved across
serotypes, elicits protective immune responses, and is
therefore a candidate for the development of new pneu-
mococcal vaccines [15].
The present study is the ﬁrst to provide evidence of the
presence of S. pneumoniae PpmA in urine samples of children
with pneumococcal infections, independently of previous
antibiotic treatment, and of its absence in such samples from
healthy children, even if their nasopharynx is colonized with
S. pneumoniae. Furthermore, the development of a simple
western blot assay for the detection of S. pneumoniae PpmA
in urine samples is reported, which establishes the necessary
basis for future randomized clinical trials of the assay with a
larger number of individuals.
Materials and Methods
Bacterial strains
Reference strains were obtained from the American Type
Culture Collection (ATCC, Manassas, USA), the National
Collection of Type Cultures (NCTC, London, UK), and the
Culture Collection University of Go¨teborg (CCUG, Go¨te-
borg, Sweden). The S. pneumoniae D39 ppmA) strain was
kindly supplied by P. W. M. Hermans, Radboud University
Nijmegen Medical Centre. Clinical isolates of Streptococcus
mutans, Streptococcus agalactiae, Haemophilus inﬂuenzae, Mor-
axella catarrhalis, Neisseria meningitidis, Legionella pneumophila,
Listeria monocytogenes, Enterococcus faecalis, Proteus mirabilis,
Providencia stuartii, Serratia marcescens and Candida albicans
were obtained from the Microbiology Laboratory of the
Hospital Universitario Central de Asturias.
Expression and puriﬁcation of PpmA
S. pneumoniae D39 (NCTC 7466) was grown in Todd–
Hewitt broth (Oxoid, Basingstoke, UK), supplemented with
0.5% yeast extract, to logarithmic phase at 37C in a 5%
CO2 atmosphere. Genomic DNA was extracted using the
E.Z.N.A. DNA puriﬁcation kit (Omega Bio-tek, Doraville,
GA, USA), following the manufacturer’s recommendations.
The ppmA gene was ampliﬁed from S. pneumoniae genomic
DNA, using PCR with the primers ppma-fd (5¢-GGAGTACAT
ATGAAGAAAAAATTATTGGCAG-3¢) and ppma-r1 (5¢-CT
CATGGATCCGGACTATTCGTTTGATG-3¢). The forward
and reverse primers contain NdeI and BamHI recognition
sequences, respectively. The ampliﬁed NdeI–BamHI-digested
ppmA fragment was cloned into pET-15b (Invitrogen, Carls-
bad, CA, USA), encoding a His(6)-tag followed by four amino
acids and a thrombin cleavage site. DNA sequencing of the
recombinant plasmid conﬁrmed the insertion of the ppmA
gene, previously described by Overweg et al. [13], and its
sequence showed 99% identity with that of the serotype 4
strain TIGR4 (ORF SP0981; accession number ABJ55379)
[16]. The ppmA recombinant sequence was different only at
the 5¢-end, due to the vector-borne extension. For the
expression of recombinant PpmA protein, the recombinant
pET-15b was transferred into electro-competent Escherichia
coli BL21 (DE3) pLysS (Novagen Inc., Madison, WI, USA) by
electroporation. Expression of recombinant PpmA was
induced with 0.1 mM isopropyl-b-D-thiogalactopyranoside at
37C for 2 h. The His-tagged 36.6-kDa PpmA was puriﬁed
to near-homogeneity from the soluble fraction of recombi-
nant E. coli lysates, using immobilized metal afﬁnity chroma-
tography with a His-Bind puriﬁcation kit (Novagen Inc.)
under native conditions, following the manufacturer’s recom-
mendations. Fractions containing the puriﬁed protein were
pooled, dialysed against phosphate-buffered saline (PBS), and
stored at )20C.
Production of hyperimmune rabbit sera
Male New Zealand White rabbits were intramuscularly
immunized with puriﬁed 36.6-kDa PpmA (100 lg/immuniza-
tion) and with 108 CFU of heat-killed whole S. pneumoniae
type 14 (CCUG 1086) and S. pneumoniae R36A (a non-
encapsulated strain; ATCC 12214), ten times at 2-week
intervals. Immunizations were performed using Freund’s
incomplete adjuvant (Sigma Chemical Co., St Louis MO,
USA). Pre-immune sera were obtained, and samples of
immune serum were drawn weekly from the marginal ear
veins of the rabbits. Pre-immune sera did not react with
PpmA or pneumococcal lysates in western blot analysis, and
were used as negative controls. The animals were bled 7 days
after the last immunization. To remove antibodies that rec-
ognized soluble E. coli proteins, lyophilized lysates were incu-
bated with polyclonal sera at 37C for 3 h and overnight at
4C; the sera were centrifuged at 10 000 g to remove bacte-
rial debris, and stored at )20C until used. Animal experi-
ments were performed in accordance with the guidelines of
the Institutional Animal Care and Use Committee of the
University of Oviedo (Spain).
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SDS-PAGE and western blot
Prior to analysis, urine samples were thawed at room
temperature, and an aliquot was centrifuged at 15 000 g
for 1 min. The supernatants were diluted in Laemmli buf-
fer [17], boiled for 5 min, and subjected to electrophore-
sis. SDS-PAGE was carried out in the Bio-Rad minigel
system (Bio-Rad Laboratories, Richmond, CA, USA) with
polyacrylamide (12%) gels. The proteins were transferred
to poly(vinylidene diﬂuoride) membranes (Inmobilon-P; Mil-
lipore, Bedford, MA, USA), using a mini-trans-blot system
(Bio-Rad Laboratories), and the membranes were blocked
in Tris-buffered saline (0.1 M Tris, 0.15 M NaCl, pH 7.5)
(TBS) containing 1% blocking reagent (Roche Diagnostics
GmbH, Mannheim, Germany) for 1 h at room temperature
or overnight at 4C. Hyperimmune rabbit antisera or
human sera were diluted 1 : 1000 in blocking solution
(TBS containing 0.1% blocking reagent) and added to the
membrane strips. After 1 h of incubation, membrane strips
were washed three times with TBS–Tween-20 (0.05%) for
10 min. Goat anti-rabbit IgG (whole molecule) peroxidase
conjugate (Sigma Chemical Co.) or anti-human c-chain per-
oxidase conjugate (Sigma Chemical Co.) (each diluted
1 : 5000) was added, and the strips were incubated for
30 min. After washing of the strips, protein was detected
using BM Chemiluminescent blotting substrate (POD)
(Roche Diagnostics GmbH) and visualized on Kodak ﬁlm.
Binax NOW S. pneumoniae test
The Binax NOW S. pneumoniae test (Binax Inc.) was per-
formed with non-concentrated urine samples obtained from
all enrolled patients according to the manufacturer’s instruc-
tions. The results were read visually after 15 min. The test
was interpreted according to the presence or absence of
pink–purple-coloured lines.
PLY-ELISA
All urine samples were tested with pneumolysin (PLY)-ELISA,
performed as previously described [11]. Brieﬂy, Combiplate
white breakable plates (Labsystems, Helsinki, Finland) were
coated with anti-PLY mouse monoclonal PLY-7 (1 lg/well)
[11] in PBS at 37C for 3 h. Plates were blocked with block-
ing buffer (ELISA-Light chemiluminescence detection system;
Tropix, Applied Biosystems, Bedford, MA, USA). Samples
were then added to the wells and incubated at 37C for 1 h
with shaking. After this, plates were incubated with rabbit
polyclonal anti-PLY IgG diluted 1 : 1000 in blocking buffer
and incubated at 37C for 30 min. Secondary anti-rabbit
IgG–alkaline phosphatase antibody (Sigma Chemicals Co.)
(1 : 5000) was added and incubated as above. Plates were
loaded and read on a Luminoskan RS (Labsystems) lumi-
nometer after automatic ﬁlling of the wells with substrate/
enhancer solution (0.4 mM CSPD with 1· Sapphire-II) and
incubation at 37C for 10 min.
Bacterial and yeast lysates
Gram-positive bacterial strains were grown overnight in
Todd–Hewitt broth (Oxoid) supplemented with yeast extract,
and Gram-negative bacteria were grown in 2xTY broth [18].
L. pneumophila and H. inﬂuenzae were grown on BCYE and
chocolate agar–fetal bovine serum plates (Oxoid), respec-
tively. C. albicans was grown on Sabouraud agar (Oxoid). Plates
were incubated at 37C under 5% CO2 for 48–72 h. Cells
were prepared in PBS, lysed by shaking with acid-washed glass
beads (106 lm) (Sigma Chemical Co.), and centrifuged for
15 min at 3000 g. Soluble proteins were quantiﬁed at A280 nm
and adjusted to 1 g/L. For SDS-PAGE, 20 lg of protein per
lane was used. Mycoplasma pneumoniae FH and Chlamydia pneu-
moniae CWL-029 cell lysates were purchased from Microbix
Biosystems Inc. (Toronto, ON, Canada). Mycobacterium tuber-
culosis and Mycobacterium bovis cell lysates were obtained from
Unidad de Referencia Regional de Micobacterias, Hospital
Universitario Central de Asturias (Oviedo, Spain).
Patients and samples
Urine samples were collected from children potentially
infected with S. pneumoniae at Hospital Universitario Central
de Asturias (Oviedo, Spain) and from healthy children at
Centro de Salud de Lugones receiving routine clinical care,
between January 2003 and December 2006. The study was
performed as a retrospective, multicentre study; the samples
were obtained with the approval of the Hospital Universitar-
io Central de Asturias Research Ethics Committee, and
informed consent was obtained from the childrens’ parents
or guardians. Ten-millilitre urine specimens were collected in
sterile containers, using aseptic techniques, and frozen at
)70C until use.
The presence of PpmA was tested for in urine samples
collected from 84 children (47 males and 37 females). The
mean and median ages were 5.03 years (±4 years) and
4 years (newborn to 14 years), respectively. The group with
culture-proven pneumococcal infections included 14 urine
samples from patients with pneumonia (n = 9), septicaemia
(n = 1), meningitis (n = 2), sinusitis (n = 1), and a ﬁnger
infection (n = 1). The group with probable pneumococcal
infections included 23 urine samples from patients with
pneumonia (n = 15) and otitis (n = 8). The group with non-
pneumococcal infections (n = 12) included: four samples
from patients with pneumonia caused by M. pneumoniae
(n = 1), Chlamydia pneumoniae (n = 1), H. inﬂuenzae (n = 1),
and respiratory syncytial virus (n = 1); one from a patient
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with gastroenteritis due to Salmonella spp.; one from a
patient with tonsillitis due to Streptococcus pyogenes; three
from patients with a common cold; two from patients with
urinary tract infection caused by E. coli; and one from
a patient with vaginitis caused by Candida spp.. The non-
infectious disease group included samples from children with
allergic rhinitis (n = 5). The group with unknown aetiology of
disease was composed of 18 urine samples from patients
with pneumonia (n = 14), otitis media (n = 2), sinusitis
(n = 1), and conjunctivitis (n = 1), and all were discarded
from test performance calculations. The group of healthy
individuals included 12 without clinical or radiological signs of
pneumonia or infection; they had not received any antibiotic
treatment during the preceding week.
Microbiological analysis and diagnostic criteria
Nasopharyngeal swab samples were taken using a calcium
alginate-tipped swab on a ﬂexible aluminium wire (TRAN-
SWAB; Medical Wire and Equipment Co., Ltd, Corsham,
UK) and streaked onto horse blood (5%) agar supplemented
with gentamicin (5 mg/L); the plates were incubated in 5%
CO2 for 24 h. All S. pneumoniae isolates were identiﬁed
according to colony morphology, Gram stain, optochin sus-
ceptibility, and bile solubility.
All urine samples were cultured to control for any cross-
reactivity. Cultures of blood (ESP system; Difco Laboratories,
Detroit, MI, USA), cerebrospinal ﬂuid, ascites, pleural ﬂuid,
tracheal aspirates, sputum, urine and pus, and of otic and vagi-
nal samples, were performed according to standard microbio-
logical methods [19]. Standard methodology was used for the
microimmunoﬂuorescence, virus culture and shell-vial assays
[20]. Speciﬁc monoclonal ﬂuorescein isothiocyanate-conju-
gated antibodies were obtained from Vircell S.L. (Granada,
Spain). A microimmunoﬂuorescence test was performed for
detection of speciﬁc antibodies against Chlamydia pneumoniae
in patient sera. Commercial ELISA tests were used for detec-
tion of IgM against M. pneumoniae and Chlamydia pneumoniae
(Vircell S.L.). Commercial complement ﬁxation tests were
used for detection of IgM/IgG against adenovirus and respira-
tory syncytial virus (Virion; Institute Virion Ltd, Ru¨schlikon,
Switzerland). All commercial tests were performed according
to the manufacturers’ instructions. The diagnosis of acute
infection was considered when the IgM test result was posi-
tive or when a four-fold or greater rise in IgM and IgG titres
was observed in sera taken at 3-week intervals.
The diagnosis of pneumococcal infection was established
on the basis of standard radiological, clinical and laboratory
criteria. Patients were classiﬁed as having pneumonia if they
presented with an acute illness with the presence of a new
or progressive inﬁltrate seen on a chest radiograph, in addi-
tion to at least two of the following symptoms: fever, cough,
shortness of breath, and pleuritic chest pain. Patients were
classiﬁed as having culture-proven pneumococcal infection
when S. pneumoniae was isolated from blood (n = 9), cere-
brospinal ﬂuid (n = 2), pleural ﬂuid (n = 1), ascitic ﬂuid
(n = 1), or pus (n = 1). Patients were classiﬁed as having
probable pneumococcal pneumonia when S. pneumoniae was
isolated from tracheal aspirates (‡106 CFU/mL) (n = 4) or
sputum (polymorphonuclear neutrophil/squamous epithelial
cell ratio ‡2 or Q (quality) score ‡ +1 on Gram stain)
(n = 1), or when both Binax NOW S. pneumoniae urinary
antigen (Binax Inc.) and PLY-ELISA urine test results were
positive (n = 12). Patients were classiﬁed as having probable
pneumococcal otitis media when S. pneumoniae was isolated
from otic exudates, and both Binax NOW S. pneumoniae uri-
nary antigen (Binax Inc.) and PLY-ELISA urine test results
were positive (n = 8). The diagnosis of urinary tract infection
was considered if >105 CFU/mL of a single bacterium was
found in urine cultures. Non-infectious diseases were diag-
nosed according to standard criteria.
Multiple alignments of protein sequences
The identiﬁcation of putative PPIases was performed using
the BLASTP program [21] at The National Center for Bio-
technology Information (NCBI; http://www.ncbi.nlm.nih.gov/
blast/Blast.cgi) and the protein sequences of Streptococcus
sanguinis SK36, (YP1034736), S. mutans UA159 (NP721076),
S. agalactiae A909 (YP329554), S. pyogenes MGAS10270
(YP598812), Enterococcus faecalis V583 (NP814435) and Liste-
ria monocytogenes strain 4b F2365 (YP014061) were retrieved
from the NCBI protein data base. The PpmA sequence of
S. mitis was retrieved from the Institute for Genomic
Research database (http://www.tigr.org). Protein sequences
were aligned using the ClustalW programme (http://www.
ebi.ac.uk/clustalw). Calculation of the percentage of amino
acid identity was carried out using the LALIGN program
(http://www.ch.embnet.org/software/LALIGN_form.html) [22].
The theoretical lipoprotein signal peptide-cleaving site was
predicted using the Lipop 1.0 Server (http://www.cbs.dtu.dk/
services/LipoP/) [23]. Calculation of percentage of similarity
of the sequences was carried out using EMBOSS Pairwise
Alignment Algorithms (http://www.ebi.ac.uk/Tools/emboss/
align/index.html). The theoretical molecular masses of the
predicted proteins were calculated using the Compute pI/
Mw tool on the ExPASy server (http://www.expasy.ch/tools/
pi_tool.html).
Statistical analysis
The data were analysed with GraphPad PRISM software
(v.4.00 for Windows; GraphPad Software, San Diego, CA,
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USA). CIs were calculated using Wilson’s method. We used
the chi-square test or, when appropriate, Fisher’s exact test
to compare proportions of qualitative variables. The limit of
statistical signiﬁcance was set at a p-value of 0.05.
Results
Detection of PpmA using western blot
In order to produce a hyperimmune anti-PpmA rabbit antise-
rum, expression and puriﬁcation of recombinant PpmA was
carried out. After induction of recombinant E. coli cultures,
two main protein bands were observed at 32 and 36 kDa
(Fig. 1a, lane 3). The theoretical molecular mass of PpmA
(34.4 kDa) increased to 36.6 kDa in the recombinant
protein, owing to fusion at the N-terminus with a His-tag fol-
lowed by a thrombin cleavage site. The predicted theoretical
molecular masses (Fig. 1d) of the protein with (36.6 kDa)
and without (32.4 kDa) lipoprotein signal peptide were very
similar to the molecular masses of proteins observed after
induction. In order to conﬁrm that both proteins were
recombinant PpmA, lysates of E. coli were assayed using
different sera. Proteins reacted with rabbit anti-heat-killed
S. pneumoniae type 14 and anti-unencapsulated S. pneumoniae
R36A antisera, and with two adult pneumococcal pneumonia
patient sera (Fig. 1b). His-tagged PpmA was puriﬁed to near-
homogeneity using immobilized metal afﬁnity chromatogra-
phy (Fig. 1a). Serum from rabbits immunized with 36.6-kDa
puriﬁed protein showed reactivity against 32-kDa and
36-kDa PpmA in recombinant E. coli lysates (Fig. 1c, lane 1).
Hyperimmune rabbit antiserum also reacted with a 34.4-kDa
protein from S. pneumoniae D39 lysates, and no reactivity
was observed against S. pneumoniae D39 ppmA) mutant
lysates (Fig. 1c, lanes 2 and 3).
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FIG. 1. Characterization of recombinant pro-
teinase maturation protein A (PpmA) and
hyperimmune rabbit antisera. (a) Expression
and puriﬁcation of recombinant PpmA. Lane 1:
molecular mass markers. Lane 2: PpmA
recombinant Escherichia coli BL21 (DE3) pLysS
cultures before isopropyl thio-b-D-galactoside
(IPTG) induction. Lane 3: PpmA recombinant
E. coli BL21 (DE3) pLysS cultures after IPTG
induction, showing main protein bands
(arrows). Lane 4: soluble cell lysate. Lane 5:
immobilized metal afﬁnity chromatography
(IMAC) unbound proteins. Lanes 6–9: IMAC
eluted protein fractions. (b) PpmA recombi-
nant E. coli lysates were incubated with rabbit
anti-Streptococcus pneumoniae type 14 antise-
rum (lane 1), anti-S. pneumoniae R36A antise-
rum (lane 2), and pneumococcal pneumonia
patient sera (lanes 3 and 4). (c) Anti-PpmA
hyperimmune rabbit antiserum was incubated
with PpmA recombinant E. coli lysate (lane 1),
S. pneumoniae D39 wild-type lysate (lane 2),
S. pneumoniae D39 ppmA) lysate (lane 3), and
a urine sample from a paediatric patient with
pneumococcal pneumonia (lane 4). (d) Sche-
matic illustration of the recombinant PpmA
full expression cassette, showing the theoreti-
cal molecular masses of the different
expressed proteins.
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Anti-PpmA hyperimmune rabbit antiserum
The speciﬁcity of the anti-PpmA hyperimmune rabbit anti-
serum was tested against lysates from nasopharyngeal com-
mensal bacteria and microorganisms known to cause
pneumonia, sinusitis, otitis and urinary tract infections in
children (Table 1). In western blot analysis, anti-PpmA anti-
serum recognized proteins with relative molecular masses
ranging between 30 and 40 kDa, in Streptococcus spp. and
Enterococcus faecalis lysates. BlastP homology searches
revealed that pneumococcal PpmA shares sequence iden-
tity/similarity with PPIases from other streptococci (Fig. 2).
The protein sequences of S. mitis, S. sanguinis, S. mutans,
S. agalactiae, S. pyogenes and Enterococcus faecalis showed
percentages of identity with S. pneumoniae PpmA of 93.6%,
57.6%, 46.4%, 47.5%, 40.1%, and 37.8%, respectively. Per-
centages of similarity were 97.1%, 74.8%, 65.7%, 66.4%,
57.6%, and 56%, respectively. PpmA identity and similarity
with that of other Gram-positive bacteria, e.g. Listeria mon-
ocytogenes, were 29.2% and 52.8%, respectively. The pre-
dicted molecular masses of these proteins were consistent
with those in antibody-stained bands observed in western
blot analysis (Table 1).
Detection of PpmA in urine samples
Hyperimmune rabbit antiserum reacted with a 34-kDa pro-
tein in urine samples from children with pneumococcal infec-
tion. A representative result of a western blot analysis is
shown in Fig. 1c, lane 4. The results of PpmA-based western
blot analyses of paediatric urine samples are shown in
Table 2. The sensitivity, speciﬁcity, and positive and negative
predictive values of the diagnostic test based on the detec-
tion of PpmA by western blot analysis were 57.1%, 100%,
100%, and 59.2%, respectively. Secreted PpmA was observed
in eight of 12 children with life-threating pneumococcal infec-
tions, with sensitivity and negative predictive values of 66.7%
and 87.9%, respectively. In contrast, 100% of the urine sam-
ples from the healthy, non-pneumococcal and non-infectious
disease groups yielded negative PpmA results. PpmA was
also detected in urine samples from adults with culture-
proven pneumococcal pneumonia, and no reactivity was
observed in urine samples from non-pneumococcal pneumo-
nia patients (data not shown). The main characteristics of
the paediatric patients with pneumococcal infections and the
results obtained with other urinary antigen tests, as corre-
lated with the PpmA test results, are shown in Table 3. No
signiﬁcant differences were found in terms of gender or
nasopharyngeal pneumococcal carriage. Half of the patients
in the present study had been treated with antibiotics before
the time of collection of the clinical specimens. The western
blot was positive for PpmA for six of 17 (35.3%) patients
who had received prior treatment with antibiotics, and for
nine of 17 (52.9%) who had not received prior antibiotic
treatment; this difference was not statistically signiﬁcant.
In the culture-proven pneumococcal infection group, 13 of
14 (92.9%) children were positive according to the low-spec-
iﬁcity Binax NOW S. pneumoniae urinary antigen test (Binax
Inc.), whereas 11 of 14 (78.6%) and eight of 14 (57.1%) were
positive with the speciﬁc PLY-ELISA and PpmA western blot
assay, respectively (Table 4). Therefore, 11 of 14 (78.6%)
children were diagnosed as positive when one or both pro-
tein-speciﬁc antigen tests were used.
Discussion
This study found the presence of S. pneumoniae PpmA in
urine, and examined its usefulness in the diagnosis of pneu-
mococcal infections in children. Recombinant, full-length
PpmA without lipoprotein signal peptide has been previously
expressed in E. coli, in order to study its immunogenicity
TABLE 1. Reactivity of hyperimmune anti- proteinase
maturation protein A (PpmA) rabbit antiserum against
pathogenic and non-pathogenic commensal bacterial lysates
Microorganisma
Reactivity of anti-PpmA
antiserum
(molecular mass, kDa)b
Streptococcus pneumoniae D39 (NCTC 7466) + (34)
Streptococcus mitis ATCC 33399 + (34)
Streptococcus sanguinis ATCC 10556 + (36)
Streptococcus mutans + (36)
Streptococcus agalactiae + (36)
Streptococcus pyogenes ATCC 19615 + (38)
Streptococcus salivarius ATCC 7073 + (38)
Streptococcus oralis ATCC 35037 + (35)
Streptococcus anginosus ATCC 12395 + (35)
Haemophilus inﬂuenzae )
Moraxella catarrhalis )
Neisseria meningitidis )
Legionella pneumophila )
Mycoplasma pneumoniae FHc )
Chlamydia pneumoniae CWL-029c )
Klebsiella pneumoniae ATCC 13883 )
Mycobacterium tuberculosis )
Mycobacterium bovis )
Pseudomonas aeruginosa ATCC 27853 )
Listeria monocytogenes )
Enterococcus faecalis + (37)
Proteus mirabilis )
Proteus vulgaris ATCC 13315 )
Providencia stuartii )
Candida albicans )
Enterobacter cloacae ATCC 23355 )
Staphylococcus aureus ATCC 25923 )
Escherichia coli ATCC 25922 )
Serratia marcescens )
aCollection strains and clinical isolates were used. Clinical isolates were
obtained from patients at the Microbiology Laboratory of the Hospital Universi-
tario Central de Asturias.
bRelative molecular mass of the proteins recognized.
cMycoplasma pneumoniae FH and Chlamydia pneumoniae CWL-029 cell lysates
were purchased from Microbix Biosystems Inc., Toronto, Canada. Cells were
lysed, and 20 lg of total protein per lane was used for antigen detection using
western blots.
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[15,24–26], as the protein has a surface-exposed C-terminal
domain, whereas the N-terminus is most probably covalently
bound to the cell membrane [13]. We selected expression
of full-length protein in E. coli and subsequent polyclonal anti-
serum production in rabbits. Two protein bands correspond-
ing to PpmA migrated in SDS-PAGE gels, suggesting that
they corresponded to PpmA with and without the lipopro-
tein signal peptide, as the molecular masses matched the
molecular masses predicted for the processed and unpro-
cessed protein. Furthermore, after puriﬁcation, only the
higher molecular mass protein was obtained, suggesting that
the 32.4-kDa protein had lost the N-terminal His-tag. This
FIG. 2. Multiple alignment of parvulin-like peptidyl-prolyl cis–trans isomerases (PPIases) and proteinase maturation protein A (PpmA). Protein
sequences were aligned using the ClustalW programme and manually coloured. The predicted signal sequence and lipid-binding site of PpmA is
underlined. Regions of 100% identity with PpmA of Streptococcus pneumoniae are shown in dark grey. Light grey shading of residues indicates sim-
ilarity. Numbers to the left indicate the location within the amino acid sequence.
CMI Garcı´a-Sua´rez et al. PpmA-based western blot 449
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 443–453
protein was the most prominent after induction, probably
because the lipoprotein signal peptide of Gram-positive
bacteria is recognized by E. coli signal peptidase II, even
though lipoprotein signal peptides of Gram-positive bacteria
differ from those of Gram-negative bacteria [23]. It was sup-
posed that both proteins have diacylglycerol attached to the
thiol of the conserved cysteine, which should reduce its solu-
bility. However, most probably because of the high levels of
expression after induction in E. coli, a low percentage of the
proteins still remained in the soluble fraction. His-tagged
protein was immunogenic in rabbits.
PpmA is homologous to the members of the ubiquitous
family of parvulin-like peptidyl-prolyl isomerases, and is
widely represented among bacteria [12,27]. One urine sam-
ple from a patient with S. pyogenes infection was tested, and
no reactivity was observed, probably because of the low
amounts of S. pyogenes PpmA homologue released into the
urine. However, urine samples from patients with Enterococ-
cus faecalis infection will need to be tested in order to assess
potential cross-reactivity. These results are consistent with
the low level of identity observed among parvulin-like
PPIases retrieved from the protein databases. PpmA shares a
high degree of amino acid sequence identity/similarity only
with the proteinase maturation protein of S. mitis, and has a
lower degree of identity/similarity with parvulin-like PPIases
of Streptococcus spp. Interestingly, the present results conﬁrm
the presence of PpmA cross-reactive epitopes in commensal
bacteria co-colonizing the nasopharyngeal niche, as previously
suggested [24]. These ﬁndings explain why a correlation
between anti-PpmA antibody titres and pneumococcal car-
riage or infection cannot be established, even though PpmA
is an immunogenic protein [25,26]. Presumably, early in life,
the very ﬁrst acquisition of microﬂora on the nasopharyngeal
mucosa, in particular of streptococci, leads to a systemic
antibody response against PpmA.
TABLE 3. Main characteristics of patients with pneumo-
coccal infections as correlated with positive urinary
proteinase maturation protein A (PpmA) antigen test
results
Characteristics (n = 37) Patient no.
No. of
positive
samples (%) 95% CI p
Gender
Male 21 10 (47.6) 28.3–67.6 0.8150
Female 16 7 (43.8) 23.1–66.9
Nasopharyngeal carriage
Positive 10 4 (40.0) 16.7–68.8 0.7256
Negative 27 13 (48.2) 30.7–66.0
Age
£2 years 10 8 (80.0) 47.9–95.4 0.0625
>2 years 27 11 (40.7) 24.5–59.3
Streptococcus pneumoniae blood culture
Positive 9 5 (55.6) 26.6–81.2 0.7034
Negative 28 12 (42.9) 26.5–61.0
Binax NOW test
Positive 35 17 (48.6) 33.0–64.4 0.4895
Negative 2 0 (0.0) 0.0–71.0
PLY-ELISA test
Positive 31 16 (51.6) 34.8–68.0 0.1886
Negative 6 1 (16.7) 1.1–58.2
Diagnosis
Pneumonia 24 13 (54.2) 35.1–72.1 0.1728
Othersa 13 4 (30.8) 12.3–57.9
Previous antibiotic treatment
Yes 17 6 (35.3) 17.2–58.8 0.3001
No 17 9 (52.9) 31.0–73.8
Undetermined 3 2 (66.7) 20.2–94.4
aIncluding septicaemia (n = 1), meningitis (n = 2), otitis media (n = 8), sinusitis
(n = 1), and a ﬁnger infection (n = 1) due to Streptococcus pneumoniae.
TABLE 4. Comparison of three urinary antigen test results
in the same urine samples from children with proven
pneumococcal infections
Patient
no. Diagnosis
Streptococcus
pneumoniae
culture-positive
Binax
NOW PLY-ELISA
PpmA
western
blot
1 Pneumonia Blood + + +
2 Pneumonia Blood + + +
3 Pneumonia Blood + + +
4 Pneumonia Blood + + +
5 Pneumonia Blood + + +
6 Pneumonia Blood + + )
7 Pneumonia Blood + ) )
8 Pneumonia Pleural ﬂuid + + +
9 Pneumonia Ascitic ﬂuid + + +
19 Meningitis Cerebrospinal ﬂuid + + +
11 Meningitis Cerebrospinal ﬂuid + ) )
12 Septicaemia Blood + + )
13 Sinusitis Blood ) ) )
14 Finger infection Pus + + )
PpmA, proteinase maturation protein A.
TABLE 2. Detection of proteinase maturation protein A in
urine samples of paediatric patients in relation to patient
condition group
Group (n = 84)
Patient
no.
No. of
positive
samples (%) 95% CI
Culture-proven pneumococcal infectionsa 14 8 (57.1) 32.6–78.7
Pneumonia, meningitis, septicaemia 12 8 (66.7) 38.8–86.5
Othersb 2 0 (0) 0.0–70.0
Probable pneumococcal infections 23 9 (39.1) 22.1–59.3
Pneumoniac 15 6 (40) 19.7–64.3
Otitis mediad 8 3 (37.5) 13.5–69.6
Non-pneumococcal infections 12 0 (0) 0.0–28.2
Pneumonia 4 0 (0) 0.0–54.6
Otherse 8 0 (0) 0.0–37.2
Non-infectious diseases 5 0 (0) 0.0–48.9
Healthy subjects 12 0 (0) 0.0–28.2
Unknown aetiology 18 2 (11.1) 1.9–34.1
aStreptococcus pneumoniae was isolated from blood (n = 9), cerebrospinal ﬂuid
(n = 2), pleural ﬂuid (n = 1), ascitic ﬂuid (n = 1), and pus (n = 1).
bSinusitis (n = 1) and ﬁnger infection (n = 1).
cS. pneumoniae was isolated from tracheal aspirates (n = 5), sputum (n = 1), or
both; Binax NOW S. pneumoniae urinary antigen (Binax Inc.) and PLY-ELISA
urine test results were positive (n = 12).
dS. pneumoniae was isolated from otic exudates, and both Binax NOW S. pneu-
moniae urinary antigen (Binax Inc.) and PLY-ELISA urine test results were posi-
tive (n = 8).
eGastroenteritis caused by Salmonella spp. (n = 1), tonsillitis caused by Strepto-
coccus pyogenes (n = 1), common cold (n = 3), urinary infection caused by Esc-
herichia coli (n = 2), and vaginitis caused by Candida spp. (n = 1).
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Owing to the commensal nature of S. pneumoniae, espe-
cially in children, the key factor in the laboratory diagnosis
of invasive pneumococcal infections is the differentiation
between infection and colonization. The limitation to the
application of the Binax NOW test for diagnosing pneumo-
coccal infections in children is that false-positive results are
obtained with samples from healthy children who are naso-
pharyngeal carriers of S. pneumoniae. Therefore, this test
can give positive results in patients with non-pneumococcal
infections who are S. pneumoniae carriers. In contrast, the
test for PpmA was speciﬁc for pneumococcal infections and
gave negative results for S. pneumoniae nasopharyngeal car-
riers. Previously, the detection of pneumolysin in urine
samples for the differentiation between colonization and
invasive pneumococcal infections in children has been
reported by this group [11]. All urine samples from healthy
carriers tested negative for the antigen, despite the abun-
dance of PpmA in the transparent colony-type variants
selected during nasopharyngeal colonization [27]. The
presumed different antigenic composition of colonizing and
invasive pneumococci has been investigated repeatedly in
the context of pneumococcal virulence gene expression,
and this has demonstrated that the mechanism of pneumo-
coccal pathogenesis is highly complex and multifactorial and
that it remains unclear [28–31]. The key for discriminating
between healthy carriers and patients might be related to
the nature of the antigens and their capacity to cross the
renal barrier.
The diagnostic potential of PpmA detection in urine was
studied using western blot analysis. The test used cannot be
considered to be a rapid clinical diagnostic test; nevertheless,
it is a helpful tool with which to evaluate the presence of
new antigens in urine samples, and could be transformed
into an ELISA or immunochromatographic assay subsequent
to the preparation of anti-PpmA monoclonal antibodies.
Although detection of PpmA in patients with pneumococcal
infection was associated with very poor sensitivity and nega-
tive predictive values, detection of PpmA in patients in
whom S. pneumoniae was isolated from blood or other ster-
ile ﬂuids notably increased the diagnostic validity. Interest-
ingly, these results were very close to those obtained with
pneumolysin detection in urine using an ELISA assay [11].
Several factors could be involved in the low sensitivity
observed in the western blot assay. To our knowledge, there
are no data regarding ppmA expression levels in vivo during
the progress of pneumococcal infection, or regarding the sta-
bility of PpmA released into the urine. However, we specu-
late that protein levels in urine are correlated with the
spread of pneumococci. On the other hand (and on the basis
of results obtained with Binax NOW), it seems reasonable
to think that the number of PpmA molecules per cell could
be lower than that of C-polysaccharide.
The strategy of using the Binax NOW S. pneumoniae
assay as a primary screen, and in addition the PLY-ELISA
and PpmA assays with Binax NOW-positive samples, could
improve the diagnostic accuracy for pneumococcal infec-
tions. Although protein antigen tests are of relatively low
sensitivity, the speciﬁcity of the PLY and PpmA assays is
higher than that of Binax NOW, and therefore positive
results obtained with the two assays indicate true pneu-
mococcal infections, increasing the accuracy of diagnosis of
pneumococcal infections in children. The kinetics of PpmA
release into the urine of patients with pneumococcal
infection were not studied here. A larger, prospective
study of paediatric populations with controlled immuniza-
tion status to evaluate the relevance of the detection of
this antigen in urine will be conducted in the future in this
laboratory.
There was a near-signiﬁcant (p 0.06) difference between
patients under 2 years of age (80% positive) and patients
over 2 years of age (40% positive). Although we have no
reliable explanation for this ﬁnding, it could be due to dif-
ferences in immunological status, as has been suggested
for the C-polysaccharide [5]. Previous studies have shown
that antibiotics could inﬂuence the production and release
of bacterial virulence factors [32–35]. The diagnosis of
S. pneumoniae infection in adults based on the Binax
NOW urinary antigen test (Binax Inc.) has been estab-
lished more often in patients who had not received antibi-
otics before the test [36]. In the present study (probably
owing to the limited number of patients), no correlation
between PpmA antigenuria and previous antibiotic treat-
ment could be established.
This study shows for the ﬁrst time that the kidney barrier
in patients with pneumococcal infection is permeable to the
S. pneumoniae protein PpmA, resulting in its excretion in
urine, which can be detected using western blots. Despite
the limited sensitivity of the PpmA detection assay, the avail-
ability of this simple immunoassay using samples obtained
with non-invasive procedures, e.g. urine, is expected to trig-
ger further research into the usefulness of pneumococcal
protein antigens as differential biomarkers of pneumococcal
carriage. Until now, conventional assays of antigenuria have
not provided such markers.
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